Neurogenomics

Circular Genomics Announces Partnership on Alzheimer’s Disease Biomarker Research

Retrieved on: 
Wednesday, September 6, 2023
Partnership, Drug development, Neurogenomics, Small RNA, Genomics, DSM-IV codes, Ageing, Research, Biomarker, RNA, Washington University in St. Louis, Dementia, Heart, The Cyprus Institute of Neurology and Genetics, Memory, Blood, Informatics, Washington University School of Medicine, George Washington University School of Medicine & Health Sciences, Neurology, Diagnosis, Medical imaging, Medical device, Genetics

Albuquerque, NM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry, has announced a partnership with leading Alzheimer’s genomics expert Dr. Carlos Cruchaga to explore the role of circRNAs as blood biomarkers for early diagnosis and treatment of Alzheimer’s Disease.

Key Points: 
  • Albuquerque, NM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry, has announced a partnership with leading Alzheimer’s genomics expert Dr. Carlos Cruchaga to explore the role of circRNAs as blood biomarkers for early diagnosis and treatment of Alzheimer’s Disease.
  • The work will expand upon the company’s ongoing primary depression research program.
  • “We are honored to expand our work with the help of neurodegeneration expert in circRNAs, Dr. Cruchaga,” said Dr. Paul Sargeant, CEO of Circular Genomics.
  • The collaboration with Dr. Cruchaga will also involve the co-application of grant proposals to help further advance the research and development of a circRNA-based assay for Alzheimer’s disease.

City of Hope appoints David W. Craig, Ph.D., as founding chair of its new Department of Integrative Translational Sciences within its Beckman Research Institute

Retrieved on: 
Thursday, June 29, 2023
City of Hope National Medical Center, Translational Genomics Research Institute, City of Hope, University, Keck School of Medicine of USC, Neurogenomics, Diabetes, Genomics, Biotechnology, National Cancer Institute, Research, USC, College of Engineering (KNUST), Science, City, Publication, Patient, Sequence, University of Washington School of Medicine, Medicine, Faculty, Reference genome, Beckman Research Institute, Health, Deana, Data science, Pharmaceutical industry, Management, Antibiotics, Hope

LOS ANGELES, June 29, 2023 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, today announced that effective June 30, David W. Craig, Ph.D., will be professor and founding chair of its newly created Department of Integrative Translational Sciences within Beckman Research Institute of City of Hope. Craig also will serve as deputy director of translational sciences at Beckman Research Institute and associate director of data science for City of Hope's National Cancer Institute-designated comprehensive cancer center in Los Angeles, which is the basic and clinical research innovation hub for its national cancer system.

Key Points: 
  • "We are excited to welcome Dr. Craig to City of Hope and look forward to his leadership in translational research that will contribute to innovative, personalized treatment for City of Hope patients throughout the United States."
  • The new Department of Integrative Translational Sciences will focus on precision measurement, data science and diversity.
  • It will seek to further improve both translational outcomes as well as the science underpinning the use of precision medicine.
  • Craig joins City of Hope from the University of Southern California, where he was co-director of the Institute of Translational Genomics and vice chair of the Department of Translational Genomics at Keck School of Medicine of USC.

Twist Bioscience Launches 96-Plex Library Prep Kit for Low Pass High Throughput Next-Generation Sequencing

Retrieved on: 
Monday, December 20, 2021
Other Health, Research, General Health, Pharmaceutical, Technology, Hospitals, Genetics, Science, Nanotechnology, Biotechnology, Medical Supplies, Health, Method, U.S. Securities and Exchange Commission, Agriculture, Idiopathic pulmonary fibrosis, Genome informatics, Genomics, NGS, Biology, Genome, Private Securities Litigation Reform Act, Scripps Research, Acquisition, Annual report, NASDAQ, Doctor of Philosophy, Risk, SEC, Silicon, Associate professor, Drug discovery, Octant, CEO, Engineering, IPF, DNA, Associate, Security (finance), Twist Bioscience, Synthetic biology, Martek Biosciences Corporation, GBS, Technology, Translational Genomics Research Institute, Fine chemical, Neurogenomics

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of synthetic DNA using its silicon platform, today announced the launch of the Twist 96-Plex Library Prep Kit, a high-performance, cost-effective preparation kit for next-generation sequencing (NGS).

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of synthetic DNA using its silicon platform, today announced the launch of the Twist 96-Plex Library Prep Kit, a high-performance, cost-effective preparation kit for next-generation sequencing (NGS).
  • We found the Twist 96-Plex Library Prep Kit!
  • Library preparation is a major bottleneck for sequencing workflows, from both a timing and cost perspective.
  • The Twist 96-Plex Library Prep Kit includes a robust PCR-like workflow for ultra-high throughput library construction that allows customers to use a small amount of sequencing data to generate high-quality genotype calls across the entire genome.

uMETHOD Health Announces the Release of a Revolutionary Methodology to Help Prevent Alzheimer's Disease and Cognitive Decline

Retrieved on: 
Thursday, June 18, 2020
RTT, Psychiatric diagnosis, Psychiatry, Cognitive disorders, Learning disabilities, Branches of biology, Neuroscience, Dementia, Alzheimer's disease, Neurogenomics, Memory disorder

The ExtND METHOD enables doctors to have a straightforward way to practice and prevent brain decline, by providing personalized plans tailored to each individual.

Key Points: 
  • The ExtND METHOD enables doctors to have a straightforward way to practice and prevent brain decline, by providing personalized plans tailored to each individual.
  • The biological progression of Alzheimer's disease tends to start in the brain 10 to 20 years before the onset of symptoms.
  • Each person has unique genetics and their own unique set of health factors that drive cognitive decline.
  • "Personalized methodologies, such as those developed by uMETHOD Health, are the future for prevention and treatment of complex neurological disorders.

Never-before-seen DNA recombination in the brain linked to Alzheimer's disease

Retrieved on: 
Monday, November 26, 2018
Biology, Alzheimer's disease, Neuroscience, Medicine, Neurochemistry, Amyloidosis, Abnormal psychology, RTT, Amyloid precursor protein, Genetic recombination, Alzheimer's disease research, Neurogenomics

"Gene recombination was discovered as both a normal process for the brain and one that goes wrong in Alzheimer's disease."

Key Points: 
  • "Gene recombination was discovered as both a normal process for the brain and one that goes wrong in Alzheimer's disease."
  • One hundred percent of the Alzheimer's disease brain samples contained an over-abundance of distinct APP gene variants, compared to samples from normal brains.
  • Although found in a mosaic pattern, the identical APP variants were observed in the most common form of Alzheimer's disease, further linking gene recombination in neurons to disease.
  • "These findings may fundamentally change how we understand the brain and Alzheimer's disease," says Chun.